H. Ericsson

发表

Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass.

A. Vuylsteke, Q. Milner, H. Ericsson, 2000, British journal of anaesthesia.

An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.

Tommy B Andersson, T. Andersson, H. Ericsson, 2004, Drug Metabolism And Disposition.

Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

J. Eriksson, E. Norjavaara, H. Ericsson, 2013, Diabetes, obesity & metabolism.

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor

K. Nelander, S. Skrtic, L. Gan, 2018, Clinical and translational science.

Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.

C. Regårdh, H. Ericsson, Å. Jolin-Mellgård, 1999, British journal of clinical pharmacology.

In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man.

C. Regårdh, H. Ericsson, B. Tholander, 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

L. Morrow, E. Norjavaara, H. Ericsson, 2012, Diabetes, obesity & metabolism.

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

K. Psachoulia, G. Law, H. Heerspink, 2021, Kidney international reports.

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

K. Nelander, F. Erlandsson, K. Bamberg, 2018, British journal of clinical pharmacology.

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

R. Unwin, H. Ericsson, P. Forte, 2019, Clinical and translational science.

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

U. Bredberg, K. Hoffmann, U. Eriksson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

RESPONSE: PREDICTING THE CLEARANCE OF CYP2C9 SUBSTRATES

T. Andersson, H. Ericsson, E. Bredberg, 2004, Drug Metabolism and Disposition.

Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.

L. Rydén, H. Ericsson, M. Nordlander, 2006, Cardiovascular drug reviews.

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects

K. Nelander, E. Lindstedt, H. Ericsson, 2021, Clinical Drug Investigation.

A Pooled Population Pharmacokinetic Analysis of Tesaglitazar in Patients With Type 2 Diabetes or With Manifestations Of Insulin Resistance

M. Karlsson, B. Hamrén, H. Ericsson, 2005 .

Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans.

J. Schwieler, T. Kahan, H. Ericsson, 1999, Journal of cardiovascular pharmacology.

Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions

H. Lennernäs, Kajsa P. Kanebratt, H. Ericsson, 2018, Drug Metabolism and Disposition.

Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.

B. Hamrén, H Ericsson, B Hamrén, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.

A. Plowright, J. Ulander, Malin Lemurell, 2019, Journal of medicinal chemistry.

PHARMACOKINETICS AND DISPOSITION

C. Regårdh, H. Ericsson, Å. Jolin-Mellgård, 1999 .

Long-term Intravenous Infusion in Healkby Volunteers

U. Bredberg, C. Regårdh, U. Eriksson, 2006 .

Pharmacokinetics and Arteriovenous Ckvidipine Concentration following a mierences in Short-and a Long-term Intravenous Infusion in Healkby Volunteers

U. Bredberg, C. Regårdh, U. Eriksson, 2006 .

Time-dependent Cardioprotection With Calcium Antagonism and Experimental Studies With Clevidipine in Ischemic-reperfused Pig Hearts: Part I

L. Rydén, L. Johansson, H. Ericsson, 2002, Journal of cardiovascular pharmacology.

Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.

J. Schwieler, C. Regårdh, H. Ericsson, 2001, Chirality.

Pharmacokinetics and Arteriovenous Differences in Clevidipine Concentration following a Short- and a Long-term Intravenous Infusion in Healthy Volunteers

U. Bredberg, C. Regårdh, U. Eriksson, 2000, Anesthesiology.

Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.

C. Regårdh, C G Regårdh, H Ericsson, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

K. Nelander, L. Gan, E. Michaëlsson, 2020, Clinical and translational science.

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers

K. Nelander, L. Gan, E. Michaëlsson, 2019, British journal of clinical pharmacology.

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

Maria Leonsson-Zachrisson, Folke Sjöberg, F. Sjöberg, 2012, The Journal of clinical endocrinology and metabolism.

The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.

F. Sjöberg, E. Norjavaara, H. Ericsson, 2012, Diabetes research and clinical practice.

Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.

Maria Leonsson-Zachrisson, Daniel Röshammar, Maria Heijer, 2012, International journal of clinical pharmacology and therapeutics.

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients

B. Tyrberg, S. Skrtic, L. Morrow, 2018, PloS one.

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients

B. Tyrberg, S. Skrtic, L. Morrow, 2018, PloS one.

Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction

B. Merkely, E. Michaëlsson, H. Ericsson, 2023, European journal of heart failure.

Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects S

W. Vaes, Marta Pelay-Gimeno, Greggory J. Housler, 2023 .